Off-label use of recombinant activated coagulation factor VII for bleeding may raise the risk of arterial thrombosis

Internal and Emergency Medicine

Volumn 6, Issue 3, 2011, Pages 261-262

  Ferrari, Laura ^a   Podda, Gian Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

BLEEDING; CHEMICALLY INDUCED DISORDER; EDITORIAL; HUMAN; OFF LABEL DRUG USE; RISK FACTOR; THROMBOSIS;

FACTOR VIIA; HEMORRHAGE; HUMANS; OFF-LABEL USE; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOSIS;

EID: 79956314799     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0593-8     Document Type: Editorial

References (3)

1. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M (2005) A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 45: 1434-1442.
2. Magnetti S, Oinonen M, Matuszewski KA (2007) An evaluation of off-label use of recombinant activated human factor VII (NovoSeven): patient characteristics, utilization trends, and outcomes from an electronic database of US academic health centers. Pharm Ther. 32: 218-230.
3. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. N Engl J Med 363: 1791-1800.